ArticleNature communications2019

Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.

José Medina-Echeverz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.